Table 2.
Patient demographics for poor metabolisers (PM), extensive metabolisers (EM) and ultra-rapid metabolisers (URM )
| PM (n = 27) | EM (n = 413) | URM (n = 10) | |
|---|---|---|---|
| Gender: female/male (%) | 16/11 (59/41) | 180/233 (44/56) | 2/8 (20/80) |
| Age (years)a | 62 (19–84) | 62 (18–91) | 63 (44–81) |
| Karnofsky performance status (%)a* | 50 (20–90) | 70 (20–90) | 55 (30–70) |
| Body mass index (kg/m2)a | 23 (14–30) | 23 (14–41) | 23 (19–28) |
| Glomerular filtration rate (ml/min/1.73 m2)a | 77 (27–239) | 96 (24–261) | 115 (42–194) |
| Albumin serum (g/L)a | 31 (10–49) | 33 (11–91) | 29 (22–36) |
| Time since diagnosis (months)a | 31 (0–155) | 16 (0–286) | 31 (0–79) |
| Time since opioid treatment started (months)a | 1 (0–42) | 1 (0–97) | 2 (0–21) |
| Time since last dose (hours)a | 11 (1–13) | 10 (0.1–17) | 11 (0.8–12) |
| Number of medication ex. opioidsa | 7 (3–14) | 6 (0–17) | 9 (3–12) |
| CYP2D6 inhibitor medicationb | 2 | 35 | 1 |
| CYP3A4 inhibitor medicationb | 2 | 21 | 1 |
| CYP3A4 inducer medicationb* | 0 | 2 | 2 |
| Breakthrough pain: yes/no (%) | 18 / 9 (67/33) | 256/156 (62/38) | 8/2 (80/20) |
| Cancer diagnosis: | |||
| Gastrointestinal (inclusive pancreas, liver)c | 2 | 87 | 3 |
| Lung (inclusive mesothelioma)c | 6 | 70 | 1 |
| Prostatec | 4 | 70 | 3 |
| Other urologicalc | 0 | 26 | 1 |
| Breastc* | 8 | 56 | 0 |
| Female reproductive organsc | 1 | 33 | 0 |
| Haematologicalc | 1 | 29 | 0 |
| Head and neckc | 1 | 10 | 0 |
| Sarcomac | 1 | 8 | 1 |
| Skinc | 1 | 8 | 0 |
| Otherc | 2 | 23 | 1 |
| Unknown originc | 1 | 12 | 0 |
| More than one diagnosisc | 1 | 17 | 0 |
*p < 0.05
aMedian (minimum to maximum)
bNumber of users
cNumber